Skip to main content

Advertisement

Log in

Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364:775–776

    Article  PubMed  Google Scholar 

  2. Kwak EL, Bang YJ, Camidge DR, Shaw AT et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703

    Article  PubMed  CAS  Google Scholar 

  3. Shaw AT, Yeap BY, Solomon BJ, Riely GJ et al (2011) Effect of Crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 11:1004–1012

    Article  Google Scholar 

  4. Younes A, Bartelett NL, Leonard JP, Kennedy DA et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  PubMed  CAS  Google Scholar 

  5. Van Besien K (2011) Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol 23:681–691

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Pfizer and Seattle Genetics allowing us to use Crizotinib and Brentuximab within the framework of a compassionate use program.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Ordemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ordemann, R., Stöhlmacher, J., Beuthien-Baumann, B. et al. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 92, 125–127 (2013). https://doi.org/10.1007/s00277-012-1524-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1524-0

Keywords

Navigation